Ptc Therapeutics (PTCT) Invested Capital (2012 - 2026)

Ptc Therapeutics' Invested Capital history runs 15 years deep, the most recent figure standing at $124.6 million for Q1 2026.

• In Q1 2026, Invested Capital rose 174.65% year-over-year to $124.6 million; the TTM figure through Mar 2026 stood at $124.6 million (up 174.65% YoY), while the FY2025 annual figure was -$199.3 million, up 81.54% from the prior year.
• Invested Capital was $124.6 million for Q1 2026 at Ptc Therapeutics, up from -$199.3 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $124.6 million in Q1 2026 to a low of -$1.1 billion in Q4 2024.
• Historically, Invested Capital has averaged -$452.0 million across 5 years, with a median of -$274.9 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Invested Capital slumped 552.73% in 2022, then surged 174.65% in 2026.
• A 5-year view of Invested Capital shows it stood at -$274.9 million in 2022, then tumbled by 190.38% to -$798.4 million in 2023, then sank by 35.21% to -$1.1 billion in 2024, then surged by 81.54% to -$199.3 million in 2025, then jumped by 162.5% to $124.6 million in 2026.
• The last three Invested Capital figures came in at $124.6 million (Q1 2026), -$199.3 million (Q4 2025), and -$139.2 million (Q3 2025), per Business Quant data.